Dr. Jason Mouabbi introduces the discussion on managing PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer in clinical practice, with a focus on treatment selection and practical adverse-event management.
Managing PIK3CA-Mutated HR+/HER2-Negative Advanced Breast Cancer in Clinical Practice
Dr. Jason Mouabbi discusses the role of molecular testing in guiding treatment selection for patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Proton Therapy Does Not Improve Survival in Advanced HCC Trial
4
CD47-Targeted Evorpacept Shows Durable Responses in HER2+ Gastric Cancer
5